VEEV’s 7.2% One Day Dip Begs The Question: Is DOCS Better Instead?
Doximity (DOCS) offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Veeva Systems (VEEV), suggesting you may be better off investing in DOCS
- DOCS’s Last 12 Months revenue growth was 19.4%, vs. VEEV’s 14.8%.
- In addition, its Last 3-Year Average revenue growth came in at 17.8%, ahead of VEEV’s 14.1%.
- DOCS leads on profitability over both periods – LTM margin of 40.5% and 3-year average of 36.4%.
VEEV provides cloud-based software and support services for life sciences industry, including implementation, project management, requirements analysis, solution design, and configuration across global markets. DOCS operates a cloud-based digital platform for U.S. medical professionals, primarily serving pharmaceutical companies and health systems.
Valuation & Performance Overview
| VEEV | DOCS | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 57.6 | 53.9 | DOCS |
| Revenue Growth | |||
| Last Quarter | 16.7% | 15.2% | VEEV |
| Last 12 Months | 14.8% | 19.4% | DOCS |
| Last 3 Year Average | 14.1% | 17.8% | DOCS |
| Operating Margins | |||
| Last 12 Months | 27.0% | 40.5% | DOCS |
| Last 3 Year Average | 22.0% | 36.4% | DOCS |
| Momentum | |||
| Last 3 Year Return | 31.9% | 109.5% | DOCS |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: VEEV Revenue Comparison | DOCS Revenue Comparison
See more margin details: VEEV Operating Income Comparison | DOCS Operating Income Comparison
But do these numbers tell the full story? Read Buy or Sell DOCS Stock to see if Doximity’s edge holds up under the hood or if Veeva Systems still has cards to play (see Buy or Sell VEEV Stock).
That is one way to look at stocks. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| VEEV Return | 94% | -6% | -37% | 19% | 9% | 40% | 107% | <=== | |
| DOCS Return | – | – | -33% | -16% | 90% | 28% | 35% | ||
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 11% | 100% | ||
| Monthly Win Rates [3] | |||||||||
| VEEV Win Rate | 67% | 58% | 33% | 50% | 58% | 71% | 56% | ||
| DOCS Win Rate | – | 33% | 25% | 50% | 67% | 43% | 36% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 57% | 62% | <=== | |
| Max Drawdowns [4] | |||||||||
| VEEV Max Drawdown | -14% | -11% | -41% | -2% | -11% | -0% | -13% | ||
| DOCS Max Drawdown | – | – | -52% | -41% | -18% | -7% | -20% | ||
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | <=== | |
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year up to 8/28/2025 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read DOCS Dip Buyer Analyses and VEEV Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.